Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(01): 120-121
DOI: 10.4103/ijmpo.ijmpo_6_16
Short Communication

SLC19A1 Polymorphism and Serum Methotrexate in Patients with Acute Lymphoblastic Leukemia

Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok, Thailand
,
Viroj Wiwanitkit
Department of Tropical Medicine, Hainan Medical University, Haikou, China; Department of Medicine, Faculty of Medicine, University of Nis, Nis, Serbia; Department of Biological Science, Joseph Ayobabalola University, Ilara-Mokin, Nigeria; Department of Community Medicine, Dr. DY Patil Medical University, Pune, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Acute lymphoblastic leukemia (ALL) is a common pediatric malignancy. Methotrexate is the widely used chemotherapy for ALL. The polymorphism (rs1051296) of SLC19A1 is proposed for its effect on serum methotrexate. To explain this observation, the authors hereby studied the interrelationship between SLC19A1 polymorphism and blood methotrexate level in the patients with ALL. Here, the authors use a quantum chemistry analysis for explaining of this observation.

Keywords

Acute lymphoblastic leukemia - methotrexate - polymorphism


Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A. et al. Childhood acute lymphoblastic leukemia: Progress through collaboration. J Clin Oncol 2015; 33: 2938-48
    CrossrefPubMedGoogle Scholar
  • 2 Koh K. Current treatment of pediatric acute lymphoblastic leukemia. Rinsho Ketsueki 2014; 55: 2225-32
    PubMedGoogle Scholar
  • 3 Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer 2015; 121: 3577-90
    CrossrefPubMedGoogle Scholar
  • 4 Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol 2014; 31: 62
    CrossrefPubMedGoogle Scholar
  • 5 Wiwanitkit V. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type. Indian J Cancer 2009; 46: 335-6
    CrossrefPubMedGoogle Scholar
  • 6 Dulucq S, Laverdière C, Sinnett D, Krajinovic M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol 2014; 10: 699-719
    CrossrefPubMedGoogle Scholar
  • 7 Gutierrez-Camino A, Lopez-Lopez E, Garcia-Orad A. SLC19A1 hot spot for MTX plasma concentration. Med Oncol 2014; 31: 204
    CrossrefPubMedGoogle Scholar